Moberg Pharma AB (publ) Asset Resilience Ratio
Moberg Pharma AB (publ) asset resilience ratio. Moberg Pharma AB (publ) (MOB) has an Asset Resilience Ratio of 4.15% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Moberg Pharma AB (publ) (MOB) liquidity interval to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Moberg Pharma AB (publ) (2017–2025)
Asset resilience ratio of Moberg Pharma AB (publ) from 2017 to 2025. This chart shows how Moberg Pharma AB (publ)'s Asset Resilience Ratio has changed over time. Read total liabilities of Moberg Pharma AB (publ) for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Moberg Pharma AB (publ)'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see balance sheet size of Moberg Pharma AB (publ).
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr28.33 Million | 4.15% |
| Short-term Investments | Skr0.00 | 0% |
| Total Liquid Assets | Skr28.33 Million | 4.15% |
Asset Resilience Insights
- Limited Liquidity: Moberg Pharma AB (publ) maintains only 4.15% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Moberg Pharma AB (publ) Industry Peers by Asset Resilience Ratio
Compare Moberg Pharma AB (publ)'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Jiangsu Nhwa Pharmaceutical Co Ltd
SHE:002262 |
Drug Manufacturers - Specialty & Generic | 26.45% |
|
Tibet Rhodiola Pharmaceutical Holding Co
SHG:600211 |
Drug Manufacturers - Specialty & Generic | 11.84% |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091 |
Drug Manufacturers - Specialty & Generic | 26.36% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
|
Bide Pharmatech Co. Ltd. A
SHG:688073 |
Drug Manufacturers - Specialty & Generic | 9.46% |
|
Jianmin Pharmaceutical Group Co Ltd
SHG:600976 |
Drug Manufacturers - Specialty & Generic | 20.61% |
|
Qianjiang Yongan Pharmaceutical Co Ltd
SHE:002365 |
Drug Manufacturers - Specialty & Generic | 30.38% |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078 |
Drug Manufacturers - Specialty & Generic | 0.42% |
Moberg Pharma AB (publ) Asset Resilience Ratio by Year (2017–2025)
Moberg Pharma AB (publ) asset resilience ratio by year from 2017 to 2025. The table below shows the annual Asset Resilience Ratio data for Moberg Pharma AB (publ).
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 4.15% | Skr28.33 Million ≈ $3.05 Million |
Skr682.26 Million ≈ $73.42 Million |
-0.79pp |
| 2024-12-31 | 4.94% | Skr34.91 Million ≈ $3.76 Million |
Skr706.09 Million ≈ $75.99 Million |
-2.81pp |
| 2023-12-31 | 7.76% | Skr49.25 Million ≈ $5.30 Million |
Skr634.73 Million ≈ $68.31 Million |
-0.80pp |
| 2022-12-31 | 8.55% | Skr48.28 Million ≈ $5.20 Million |
Skr564.42 Million ≈ $60.74 Million |
+0.44pp |
| 2021-12-31 | 8.12% | Skr36.60 Million ≈ $3.94 Million |
Skr450.89 Million ≈ $48.52 Million |
-15.13pp |
| 2020-12-31 | 23.25% | Skr111.73 Million ≈ $12.02 Million |
Skr480.58 Million ≈ $51.72 Million |
-0.36pp |
| 2019-12-31 | 23.61% | Skr30.84 Million ≈ $3.32 Million |
Skr130.59 Million ≈ $14.05 Million |
+22.79pp |
| 2018-12-31 | 0.82% | Skr10.32 Million ≈ $1.11 Million |
Skr1.25 Billion ≈ $134.69 Million |
+0.51pp |
| 2017-12-31 | 0.32% | Skr3.90 Million ≈ $419.44K |
Skr1.22 Billion ≈ $131.64 Million |
-- |
About Moberg Pharma AB (publ)
Moberg Pharma AB (publ), a pharmaceutical company, develops and commercializes medical products primarily in Sweden. It offers MOB-015 for the treatment of nail fungus under the Terclara brand. The company was formerly known as Moberg Derma AB (publ) and changed its name to Moberg Pharma AB (publ) in May 2013. Moberg Pharma AB (publ) was incorporated in 2006 and is based in Bromma, Sweden.